These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31352807)

  • 21. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
    Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
    Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidiabetic treatment patterns in a medicare advantage population in the United States.
    Slabaugh SL; Xu Y; Stacy JN; Baltz JC; Meah YA; Lian J; Moretz DC; Bouchard JR
    Drugs Aging; 2015 Feb; 32(2):169-78. PubMed ID: 25573537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the Adequacy of glycemiC Control in pAtients with type 2 Diabetes mEllitus treated with Metformin monotherapY at the maximal-tolerated dose (ACCADEMY) study.
    Giorda CB; Cercone S; Nada E;
    Endocrine; 2016 Jun; 52(3):507-15. PubMed ID: 26275456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin therapy in type 2 diabetes.
    Mudaliar S; Edelman SV
    Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
    Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
    Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Slow response to loss of glycemic control in type 2 diabetes mellitus.
    Brown JB; Nichols GA
    Am J Manag Care; 2003 Mar; 9(3):213-7. PubMed ID: 12643338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the role of basal and prandial insulin for optimal glycemic control.
    Horton ES
    J Am Coll Cardiol; 2009 Feb; 53(5 Suppl):S21-7. PubMed ID: 19179213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
    Pradhan AD; Everett BM; Cook NR; Rifai N; Ridker PM
    JAMA; 2009 Sep; 302(11):1186-94. PubMed ID: 19755697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
    Engel SS; Seck TL; Golm GT; Meehan AG; Kaufman KD; Goldstein BJ
    Endocr Pract; 2013; 19(5):751-7. PubMed ID: 23757615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Is there any progress in the blood glucose lowering therapy of type 2 diabetes?].
    Winkler G
    Orv Hetil; 2014 Aug; 155(31):1215-20. PubMed ID: 25095281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    ; Zeitler P; Hirst K; Pyle L; Linder B; Copeland K; Arslanian S; Cuttler L; Nathan DM; Tollefsen S; Wilfley D; Kaufman F
    N Engl J Med; 2012 Jun; 366(24):2247-56. PubMed ID: 22540912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
    Basit A; Riaz M; Fawwad A
    Vasc Health Risk Manag; 2012; 8():463-72. PubMed ID: 23028231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.